{
    "root": "313090ef-ad58-1103-e063-6394a90a7d75",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Mupirocin",
    "value": "20250325",
    "ingredients": [
        {
            "name": "POLYETHYLENE GLYCOL 400",
            "code": "B697894SGQ"
        },
        {
            "name": "POLYETHYLENE GLYCOL 3350",
            "code": "G2M7P15E5P"
        },
        {
            "name": "MUPIROCIN",
            "code": "D0GX863OA5"
        }
    ],
    "indications": "mupirocin ointment usp , 2 % indicated topical treatment impetigo due susceptible isolates staphylococcus aureus ( s. aureus ) streptococcus pyogenes ( s. pyogenes ) .",
    "contraindications": "topical . apply small amount mupirocin ointment , cotton swab gauze pad , affected area 3 times daily 10 days . cover treated area gauze dressing desired . re-evaluate patients showing response within 3 5 days . mupirocin ointment intranasal , ophthalmic , mucosal [ ( 5.2 , 5.6 ) ] . apply mupirocin ointment concurrently lotions , creams , ointments [ pharmacology ( 12.3 ) ] .",
    "warningsAndPrecautions": "gram mupirocin ointment contains 20 mg mupirocin water-miscible ointment base . mupirocin ointment usp , 2 % supplied follows : 100 x 1-g tube 50 x 1 g tube ndc 70166-355-10 ndc 70166-355-50",
    "adverseReactions": "mupirocin ointment contraindicated patients known hypersensitivity mupirocin excipients mupirocin ointment .",
    "indications_original": "Mupirocin Ointment USP, 2% is indicated for the topical treatment of impetigo due to susceptible isolates of \n       \n \n  \n       \n \n  Staphylococcus aureus (S. aureus) and \n       \n \n  \n       \n \n  Streptococcus pyogenes (S. pyogenes).",
    "contraindications_original": "For Topical Use Only.\n                     Apply a small amount of mupirocin ointment, with a cotton swab or gauze pad, to the affected area 3 times daily for up to 10 days.\n                     Cover the treated area with gauze dressing if desired.\n                     Re-evaluate patients not showing a clinical response within 3 to 5 days.\n                     Mupirocin ointment is not for intranasal, ophthalmic, or other mucosal use \n        \n  \n   \n        \n  \n   [see \n         \n   \n    \n         \n   \n    Warnings and Precautions (5.2, \n         \n   \n    \n         \n   \n    5.6)]\n        \n  \n   \n        \n  \n   .\n       \n \n  \n       \n \n  \n                     Do not apply mupirocin ointment concurrently with any other lotions, creams, or ointments \n        \n  \n   \n        \n  \n   [see \n         \n   \n    \n         \n   \n    Clinical Pharmacology (12.3)]\n        \n  \n   \n        \n  \n   .",
    "warningsAndPrecautions_original": "Each gram of mupirocin ointment contains 20 mg mupirocin in a water-miscible ointment base.\n                  Mupirocin Ointment USP, 2% is supplied as follows:\n                  \n                     \n                        \n                        \n                     \n                     \n                        \n                           \n                              100 x 1-g Tube\n                              \n                              50 x 1 g Tube\n                           \n                           \n                              NDC 70166-355-10 \n                              \n                              NDC 70166-355-50",
    "adverseReactions_original": "Mupirocin ointment is contraindicated in patients with known hypersensitivity to mupirocin or any of the excipients of mupirocin ointment."
}